<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-695X</journal-id>
<journal-title><![CDATA[Revista Clínica de Medicina de Familia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Clin Med Fam]]></abbrev-journal-title>
<issn>1699-695X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Medicina de Familia y Comunitaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-695X2017000200070</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Adecuación y seguridad en el consumo crónico de inhibidores de la bomba de protones]]></article-title>
<article-title xml:lang="en"><![CDATA[Adequacy and safety in Proton Pump Inhibitors (PPIs) chronic use]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Azpiazu Garrido]]></surname>
<given-names><![CDATA[Mercedes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñoz Hernández]]></surname>
<given-names><![CDATA[Isabel S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,C.S. de Puente del Arzobispo  ]]></institution>
<addr-line><![CDATA[Toledo ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Nuestra Señora del Prado Servicio de Digestivo ]]></institution>
<addr-line><![CDATA[Talavera de la Reina ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>10</volume>
<numero>2</numero>
<fpage>70</fpage>
<lpage>77</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-695X2017000200070&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-695X2017000200070&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-695X2017000200070&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Objetivo:  Evaluar la adecuación del uso crónico de IBP, qué factores se asocian a ella y la presencia de posibles efectos adversos.  Diseño:  Estudio observacional retrospectivo.  Emplazamiento:  Centro de Salud urbano.  Participantes:  109 de los 242 pacientes de 40 a 85 años que consumieron IBP más de 12 meses en 2013 y 2014.  Mediciones Principales:  Sexo, edad, principio activo, meses consumo, indicación, adecuación actual, comorbilidad, tratamientos crónicos y efectos adversos. Muestreo aleatorio en dos cupos médicos. Revisión de historias clínicas.  Resultados:  Edad media: 70,9 (DE: 10,1) años. Mujeres: 58,7 %. Consumió omeprazol el 83,5 %. Mediana de consumo de 96 meses (rango intercuartílico: 60-132). Se indicaron para gastroprotección (55 %), ERGE (9,2 %) y ninguna (35,8 %). El consumo actual fue adecuado en un 64,2 % (37 % en &lt;65 años frente a 73,2 % en &gt;65 años; p=0,001). Comorbilidad media de 2,3 (DE: 1,1) enfermedades, siendo la artrosis y depresión más frecuentes en mujeres y la enfermedad vascular, neumopatía y hepatopatía en hombres. El número medio de fármacos crónicos fue 5,7 (DE: 2). Neumonía (24,8 %), déficit de vitamina B12 (6,4 %) y osteoporosis (31,2 %) fueron enfermedades concomitantes durante el consumo de IBP. Los pacientes con adecuado consumo crónico de IBP se caracterizaron por tener más edad, mayor comorbilidad (principalmente enfermedad vascular y ansiedad-depresión) y tomar más fármacos (entre ellos antiagregantes, ISRS, AINEs gastrolesivos).  Conclusiones:  Se observó un consumo crónico de IBP superior a 5 años en el 75 % de la muestra. Más de un tercio consumían IBP sin indicación justificada, por tanto son necesarias medidas correctoras para mejorar la seguridad de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Objective:  To evaluate the adequacy of PPI chronic use, the factors associated to it and the presence of possible adverse effects.  Design:  Retrospective observational study.  Location:  Urban health centre.  Participants:  109 of the 242 patients aged 40 to 85 who consumed PPIs over 12 months in 2013 and 2014.  Main measures:  Sex, age, active ingredient, consumption time (months), indication, current adequacy, comorbidity, chronic treatments and presence of adverse effects. Random sampling from two doctor quotas. Review of medical records.  Results:  Average age: 70.9 (SD: 10.1) years old. Women: 58.7 %. 83.5 % consumed omeprazole. Median consumption time: 96 months (interquartile range: 60-132). PPIs were indicated for gastroprotection (55 % ), GERD (9.2 %) and nothing (35.8 %). Current consumption was appropriate in 64.2 % (37 % in aged &lt;65 vs 73.2 % in aged &gt;65, p=0.001). Average number of comorbidities was 2.3 (SD: 1.1) diseases. Osteoarthritis and depression were more common in women while vascular disease, lung disease and liver disease were more common in men. The average number of chronic medications was 5.7 (SD: 2). Pneumonia (24.8 %), vitamin B12 deficiency (6.4 %) and osteoporosis (31.2 %) were concomitant diseases during PPI consumption. Patients with appropriate PPI chronic consumption were older, had more comorbidities (mainly vascular disease and anxiety-depression), and used more medications (among them, antiplatelet drugs, SSRIs, gastroerosive NSAIDs.  Conclusions:  75 % of the sample showed a PPI chronic use of over 5 years. 35.8 % used PPIs without justified indication. Corrective measures are therefore required to improve patient safety.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Inhibidores de la Bomba de Protones]]></kwd>
<kwd lng="es"><![CDATA[Prescripción Inadecuada]]></kwd>
<kwd lng="es"><![CDATA[Seguridad del Paciente]]></kwd>
<kwd lng="en"><![CDATA[Proton Pump Inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Inappropriate Prescribing]]></kwd>
<kwd lng="en"><![CDATA[Patient Safety]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<source><![CDATA[Informe anual del Sistema Nacional de Salud 2010. Ministerio de Sanidad, Política social e Igualdad]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Ministerio de Sanidad, Política social e Igualdad</collab>
<source><![CDATA[Informe anual del Sistema Nacional de Salud 2015]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia del Pozo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio de utilización de antiulcerosos en España (2000-2008)]]></article-title>
<source><![CDATA[Inf Ter Sist Nac Salud]]></source>
<year>2009</year>
<volume>33</volume>
<page-range>49-54</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Proton pump inhibitors]]></article-title>
<source><![CDATA[NPS Medicinewise professional]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Hoyer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Machado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores de bomba, posibles consecuencias de su uso a largo plazo]]></article-title>
<source><![CDATA[Revista GEN (Gastroenterología Nacional)]]></source>
<year>2011</year>
<volume>65</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>376-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madridejos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores de la bomba de protones y el balance riesgo-beneficio]]></article-title>
<source><![CDATA[Butlletí d´informació terapéutica]]></source>
<year>2013</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>7-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonis Sanz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibidores de la bomba de protones]]></article-title>
<source><![CDATA[AMF]]></source>
<year>2012</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>218-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inhibidores de la bomba de protones ¿se puede vivir sin ellos?]]></article-title>
<source><![CDATA[Información farmacoterapéutica de la Comarca]]></source>
<year>2010</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>11-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomson A]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Sauve]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Kassam]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kamitakahara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of the long-term use of proton pump inhibitors]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2010</year>
<volume>16</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2323-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Cuén]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Irineo Cabrales]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal Magaña]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Peraza Garay]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicaciones inadecuadas en el consumo crónico de inhibidores de bomba de protones en un hospital de México Estudio transversal]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig (Madrid)]]></source>
<year>2013</year>
<volume>105</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>131-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Gerson]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Vela]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the diagnosis and management of gastroesophageal reflux disease]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2012</year>
<volume>108</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>308-28</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marzo-Castillejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mascort]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mearin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo del paciente con ERGE. Guía de práctica clínica. Actualización 2008]]></article-title>
<collab>Grupo de trabajo de la GPC sobre la ERGE</collab>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2009</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>431-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kahrilas]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical management of gastroesophageal reflux disease in adults]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Talley]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Uptodate (Monografía en internet)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burgos Lunar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Novo del Castillo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Llorente Díaz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Salinero Fort]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio prescripción-indicación de inhibidores de la bomba de protones]]></article-title>
<source><![CDATA[Rev Clin Esp]]></source>
<year>2006</year>
<volume>206</volume>
<page-range>266-70</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallés Fernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Franzi Sisó]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferro Rivera]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Condiciones clínicas y terapéuticas que requieren gastroprotección]]></article-title>
<source><![CDATA[FMC]]></source>
<year>2014</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>528-33</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>Unidad Docente de MfyC. Sector Zaragoza I</collab>
<source><![CDATA[GPC Empleo de los inhibidores de la bomba de protones en la prevención de gastropatías secundarias a fármacos]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín-Echevarría]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira Juliá]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torralba]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arriola Pereda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Dávila]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mateos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del uso de los inhibidores de la bomba de protones en un servicio de medicina interna]]></article-title>
<source><![CDATA[Rev Esp Enferm Dig (Madrid)]]></source>
<year>2008</year>
<volume>100</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>76-81</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Borobia]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Piñana]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fudio]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overuse of PPIs in patients at admission, during treatment and at discharge in a tertiary spanish hospital]]></article-title>
<source><![CDATA[Curr Clin Pharmacol]]></source>
<year>2010</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>288-97</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batuwitage]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Kingham]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Bartlett]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inappropriate prescribing of proton pump inhibitors in primary care]]></article-title>
<source><![CDATA[Postgrad Med J]]></source>
<year>2007</year>
<volume>83</volume>
<page-range>66-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Arciniegas]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Marulanda Fernández]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lúquez Mindiola]]></surname>
<given-names><![CDATA[AJ.]]></given-names>
</name>
</person-group>
<source><![CDATA[Déficit de vitamina B12 asociado al consumo de inhibidores de bomba de protones]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Colombia, Facultad de Medicina. Departamento de Medicina Interna]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<collab>Fundació Institut Catalá de Farmacología</collab>
<article-title xml:lang=""><![CDATA[Inhibidores de la bomba de protones: no son &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ protectores &amp;raquo;,» &amp;reg;,® &amp;sect;,§ &amp;shy;,­ &amp;sup1;,¹ &amp;sup2;,² &amp;sup3;,³ &amp;szlig;,ß &amp;THORN;,Þ &amp;thorn;,þ &amp;times;,× &amp;Uacute;,Ú &amp;uacute;,ú &amp;Ucirc;,Û &amp;ucirc;,û &amp;Ugrave;,Ù &amp;ugrave;,ù &amp;uml;,¨ &amp;Uuml;,Ü &amp;uuml;,ü &amp;Yacute;,Ý &amp;yacute;,ý &amp;yen;,¥ &amp;yuml;,ÿ &amp;para;,¶ , son fármacos]]></article-title>
<source><![CDATA[Butlletí groc]]></source>
<year>2016</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidelbaugh]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overutilization of proton-pump inhibitors: what the clinician needs to know]]></article-title>
<source><![CDATA[Ther Adv Gastroenterol]]></source>
<year>2012</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>219-32</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<collab>Fundació Institut Catalá de Farmacología</collab>
<article-title xml:lang=""><![CDATA[Uso prologado de inhibidores de la bomba de protones y riesgo de fracturas]]></article-title>
<source><![CDATA[Butlletí groc]]></source>
<year>2012</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>5-8</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martí-Cabrera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marti-Masanet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ríos-Navarro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Polo Peñalver]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Esplugues Mota]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<source><![CDATA[Inhibidores de la bomba de protones y la homeostasis del calcio. Artículo de Revisión]]></source>
<year>2013</year>
<publisher-name><![CDATA[Facultad de Medicina. Universidad de Valencia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inhibidores de la bomba de protones: ¿cómo se utilizan?]]></article-title>
<source><![CDATA[SACYLITE. Boletín de información terapéutica]]></source>
<year>2010</year>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
